Cancer
Breakthrough in Cancer Immunotherapy: Combinatorial Treatment Significantly Improves Tolerability Without Compromising Efficacy
Current research in cancer immunotherapy has revealed promising results in the administration of recombinant interleukin 2 (IL-2) fusion proteins. However, these treatments are often hindered by dose-limiting toxicities, including vascular leak syndrome. To address this issue, researchers from the University of Zurich have explored the therapeutic potential of co-administering signaling